Literature DB >> 16116179

CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity.

Xueshu Zhang1, Hui Huang, Jinying Yuan, Deming Sun, Wu-Shiun Hou, John Gordon, Jim Xiang.   

Abstract

It is clear that dendritic cells (DCs) are essential for priming of T cell responses against tumors. However, the distinct roles DC subsets play in regulation of T cell responses in vivo are largely undefined. In this study, we investigated the capacity of OVA-presenting CD4-8-, CD4+8-, or CD4-8+ DCs (OVA-pulsed DC (DC(OVA))) in stimulation of OVA-specific T cell responses. Our data show that each DC subset stimulated proliferation of allogeneic and autologous OVA-specific CD4+ and CD8+ T cells in vitro, but that the CD4-8- DCs did so only weakly. Both CD4+8- and CD4-8+ DC(OVA) induced strong tumor-specific CD4+ Th1 responses and fully protective CD8+ CTL-mediated antitumor immunity, whereas CD4-8- DC(OVA), which were less mature and secreted substantial TGF-beta upon coculture with TCR-transgenic OT II CD4+ T cells, induced the development of IL-10-secreting CD4+ T regulatory 1 (Tr1) cells. Transfer of these Tr1 cells, but not T cells from cocultures of CD4-8- DC(OVA) and IL-10-/- OT II CD4+ T cells, into CD4-8+ DC(OVA)-immunized animals abrogated otherwise inevitable development of antitumor immunity. Taken together, CD4-8- DCs stimulate development of IL-10-secreting CD4+ Tr1 cells that mediated immune suppression, whereas both CD4+8- and CD4-8+ DCs effectively primed animals for protective CD8+ CTL-mediated antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116179     DOI: 10.4049/jimmunol.175.5.2931

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Dendritic cell-associated lectin 2 (DCAL2) defines a distinct CD8α- dendritic cell subset.

Authors:  Shinji Kasahara; Edward A Clark
Journal:  J Leukoc Biol       Date:  2011-12-06       Impact factor: 4.962

Review 2.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

3.  Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses.

Authors:  Siguo Hao; Yongqing Liu; Jinying Yuan; Xueshu Zhang; Tianpei He; Xiaochu Wu; Yangdou Wei; Deming Sun; Jim Xiang
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 4.  Complexity of dendritic cell subsets and their function in the host immune system.

Authors:  Rahul Kushwah; Jim Hu
Journal:  Immunology       Date:  2011-06-01       Impact factor: 7.397

5.  Silencing of the TGF-β1 gene increases the immunogenicity of cells from human ovarian carcinoma.

Authors:  Huafeng Wei; Pu Liu; Elizabeth Swisher; Yuen Yee Yip; Jee Hang Tse; Kathy Agnew; Karl Erik Hellström; Ingegerd Hellström
Journal:  J Immunother       Date:  2012-04       Impact factor: 4.456

Review 6.  TGFβ in T cell biology and tumor immunity: Angel or devil?

Authors:  Eric Tu; Pei Zhi Cheryl Chia; Wanjun Chen
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

Review 7.  Dendritic cell control of tolerogenic responses.

Authors:  Santhakumar Manicassamy; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 8.  Dendritic cells as gatekeepers of tolerance.

Authors:  Ari Waisman; Dominika Lukas; Björn E Clausen; Nir Yogev
Journal:  Semin Immunopathol       Date:  2016-07-25       Impact factor: 9.623

Review 9.  Natural and Induced Tolerogenic Dendritic Cells.

Authors:  Courtney A Iberg; Daniel Hawiger
Journal:  J Immunol       Date:  2020-02-15       Impact factor: 5.422

10.  PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

Authors:  Jiqing Sai; Philip Owens; Sergey V Novitskiy; Oriana E Hawkins; Anna E Vilgelm; Jinming Yang; Tammy Sobolik; Nicole Lavender; Andrew C Johnson; Colt McClain; Gregory D Ayers; Mark C Kelley; Melinda Sanders; Ingrid A Mayer; Harold L Moses; Mark Boothby; Ann Richmond
Journal:  Clin Cancer Res       Date:  2016-12-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.